Imbria Pharmaceuticals, Inc.

ACTIVE

265 Franklin St Ste 1702, 马萨诸塞州萨福克县, Massachusetts, United Stateswww.imbria.comHolding1–10 employeesEstablished: 2018-01-01

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

45.5%

Phase 1

36.4%

Trial Status Distribution

Active, not recruiting

36.4%

Completed

45.5%

Recruiting

9.1%

Withdrawn

9.1%

Clinical Trials

Trials sponsored by this organization (11)

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

Recruiting

interventional

Oct 2025165 participants

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

Phase 2

Completed

interventional

Jun 202167 participants

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

Phase 2

Completed

interventional

Apr 202158 participants

IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

Phase 2

Completed

interventional

Apr 202149 participants

A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve angina

Phase 1

Active, not recruiting

Feb 202165 participants

A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve angina

Phase 1

Active, not recruiting

Dec 202065 participants

A research study to determine the safety of IMB-1018972 and how it helps your heart use energy more efficiently to improve angina

Phase 1

Active, not recruiting

Dec 202065 participants

A research study to learn about the effects of IMB-1018972, to try and help your heart cell use energy more efficiently, to find the best dose, and to see how safe it is. This is for patients who may be at risk for a heart condition known as diabetic cardiomyopathy (DbCM) as a complication of a type 2 diabetes mellitus (T2DM).

Phase 1

Active, not recruiting

Sep 202036 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations